Companies · Biotechnology

Catheter Connections, Inc.

SALT LAKE CITY · Biotechnology

Diligence memoA one-page analyst read on Catheter Connections, Inc. — recommendation, valuation, rhythm, risks.
$6.8M
Total raised · real
3
Rounds
2.7×
Latest step-up
Top 52%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Catheter Connections, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.19× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Catheter Connections, Inc. is one of 4291 Biotechnology companies tracked from SALT LAKE CITY. By capital raised it ranks mid-pack (ahead of 49% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2009-04-01 Raised $5.3M (real) Modeled valuation $191M (est)$5.3M$191MSeries A2009Pre-Seed · 2009-04-01 Raised $405K (real) Modeled valuation $22M (est)$405K$22MPre-Seed2009Series A · 2012-08-10 Raised $1.1M (real) Modeled valuation $39M (est)$1.1M$39MSeries A2012+$405K+$1.1MCumulative $6.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.3M · 2009
Bridge · Series A-stage$405K · 2009smaller follow-on
Series A extension$1.1M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$38.9M
Base estimate est.
$1.2M
Conservative case
$211.4M
Upside case
$4.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $191.1M · 2009-04-012009Pre-Seed · modeled $22.4M · 2009-04-01Series A · modeled $38.9M · 2012-08-102012
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
13.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$2.0M/yr
Capital velocity
17.3 yr
On record since
2009
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.9× of median
This company$6.8M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.1M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$38.9M
Sector median$64.2M

Raised more than 49% of sector peers (real $). Modeled value above 40% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #84 of 92.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)Catheter Connections, Inc. (this company) Raised $6.8M · modeled $38.9M (est)Catheter Connections, Inc.
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
Catheter Connections, Inc. this companySeries A$6.8M$38.9M0.19×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.3M2009-04-01$24.0M$191.1M90%
Pre-Seed$405K2009-04-01$2.3M$22.4M90%
Series A$1.1M2012-08-10$4.9M$38.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.3M2009-04-01
    • First recorded raise — entered as Series A.
  2. Pre-Seed$405K2009-04-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 13.1× smaller than the prior — bridge or down round.
  3. Series A$1.1M2012-08-10
    • Raised again after 40 mo — slower than the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
Intelligence
2014 ~Q2
Modeled next raise · ~20mo cadence
$2.9M
Modeled next size est.range $1.9M$4.6M
2.7×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Guy Jordan2 other2009-04
Brian Cummings1 other2009-04
Ned D Scheetz1 other2012-08
Charity D. Williams2009-04
David D. Green2012-08
Donald D. Solomon2009-04
Doug D. Wells2009-04
Guy E. Jordan2009-04
James Mercer2009-04
Michael D. Bates2009-04
Michael W. Howlett2009-04
Robert Hitchcock2009-04
Ted D. McAleer2012-08
Vicki E. Farrar2009-04
Registry & provenance

Catheter Connections, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1462574
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
OptoVista Holdings, LLCBiotechnologySeries A$7.0M$34.2Msame sector · same stage
Omnipulse Biosciences, Inc.BiotechnologySeries A$7.0M$47.8Msame sector · same stage
Regenerative Medical Solutions, Inc.BiotechnologySeries A$7.0M$39.5Msame sector · same stage
Amplifyer Bio, Inc.BiotechnologySeries A$7.1M$33.1Msame sector · same stage
Clear Creek Bio, Inc.BiotechnologySeries A$7.1M$37.1Msame sector · same stage
Kern Australis, LLCBiotechnologySeries A$6.1M$37.0Msame sector · same stage
Holobiome, Inc.BiotechnologySeries A$7.5M$39.9Msame sector · same stage
Stemina Biomarker Discovery, Inc.BiotechnologySeries A$7.9M$36.2Msame sector · same stage
Frequently asked
How much funding has Catheter Connections, Inc. raised?
Catheter Connections, Inc. has raised approximately $6.8M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Catheter Connections, Inc.'s estimated valuation?
Provath's modeled valuation for Catheter Connections, Inc. is approximately $38.9M (modeled range $1.2M–$211.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Catheter Connections, Inc. at?
Catheter Connections, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 10.
What does Catheter Connections, Inc. do and where is it based?
Catheter Connections, Inc. operates in the Biotechnology sector, based in SALT LAKE CITY.
Explore related

See where Catheter Connections, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Catheter Connections, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.